Clinical trial
PPAR-COMBO With Sulfonylurea
NCT00162175 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00162175 |
|---|---|
| Title | PPAR-COMBO With Sulfonylurea |
| Official title | A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination With Glyburide Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Sulfonylurea Therapy Alone |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metabolics Diabetes Nos |
| Intervention type | Drug |
| Interventions | Muraglitazar |
| Enrollment | 534 |
| Start date | Jul 1, 2003 |
| Primary completion | Nov 1, 2005 |
| Completion | Nov 1, 2005 |
| First posted | Sep 13, 2005 |
| Last update posted | Sep 14, 2010 |
| Countries | Argentina, Australia, Brazil, Canada, France, Germany, Italy, Mexico, Netherlands, Peru, Puerto Rico, Russia and 3 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: